Society

The Exchange: Australian Treasurer Josh Frydenberg

21 Dec 2021

With an election looming early next year, the Liberal Party’s deputy leader discusses everything from booster shots to Big Tech, climate change to China, immigration to inflation, and more. He tells Jeffrey Goldfarb how his country can overcome the many economic challenges ahead.

Davos delay will stoke gabfest demand

20 Dec 2021

January’s Swiss conflab is off, for the second year running. In 2021, Zoom calls and rival events like COP26 raised the risk Davos could lose its relevance. In 2022, enough bankers were looking forward to the slopes to imply that a summer event will still get takers.

Big Meat will channel VW-Tesla in alt-protein war

20 Dec 2021

Elon Musk stole a march on automakers, forcing them to play catchup on electric cars. A similar dynamic could play out in real and plant-based meat. The likes of Impossible Foods have a Tesla-like lead, but old hands like Tyson and JBS can use M&A to play tortoise to their hare.

Capital Calls: Bundesbank, Biogen

20 Dec 2021

Concise views on global finance: The new head of Germany's central bank is a reassuringly boring choice; cutting the price of its Alzheimer's drug could help Biogen squeeze something out of what looks like a flop.

Xi’s 2022 GDP target will be moment of truth

20 Dec 2021

One of the Chinese president’s signature policy initiatives was to curb property-related risks. That implies slower but higher quality growth: 4% or so in 2022. Outside advisers are pushing for more. The final economic decision will signal the extent of Xi Jinping’s power.

Capital Calls: McDonald’s makes ex-CEO pay

16 Dec 2021

Concise views on global finance: The fast-food chain settled its lawsuit with ousted boss Steve Easterbrook, recovering compensation now worth $105 million.

China’s metaverse will be a tiny place

16 Dec 2021

Stocks in local companies associated with digital worlds blew up in 2021. The country’s video-games industry, tech expertise and masses of disaffected youth make it an ideal place to push the bleeding edge of virtual reality. That’s precisely why Beijing is squashing it.

The Exchange: Top chef who turned his back on meat

14 Dec 2021

Daniel Humm’s Eleven Madison Park in New York garnered three Michelin stars and was voted the world’s best restaurant in 2017. But after the pandemic, the marathoning Swiss transplant pivoted his kitchen entirely towards plant-based cuisine. He tells Rob Cox why.

Longer weekends are the next economic battleground

10 Dec 2021

The United Arab Emirates is slicing half a day off the working week while companies experiment with shorter hours. A lasting shift requires a majority to follow, even as tech makes it harder to log off. But post-pandemic workers may be more willing to trade labour for leisure.

Review: An antidote to the cult of busyness

3 Dec 2021

The pandemic focused minds on life’s brevity. Oliver Burkeman delves into fruitful approaches to using that limited time in “Four Thousand Weeks”. It’s an articulate reflection on distraction, the joyless urgency of productivity hacks, and why keeping options open may be futile.

Omicron may give inflation a chance to bed in

29 Nov 2021

The new coronavirus variant could ease short-term price pressures if it triggers wider lockdowns that curb consumption. But if it prolongs supply-chain problems the reverse will be true in the longer term. Especially if cautious central bankers delay tightening monetary policy.

New Covid-19 variant raises risk of recovery limbo

26 Nov 2021

Britain and others have revived travel bans on South Africa amid a new viral mutation. Countries with low vaccination rates are most vulnerable. But if the virus evades vaccines, new lockdowns may be necessary at a time when governments and central banks have depleted firepower.

New German coalition has old problem with spending

24 Nov 2021

The three parties that will form the next government want to invest more in green and digital projects while respecting strict debt limits. Cutting budget subsidies and using off-balance-sheet vehicles may help. But the plans fall far too short of big-spending peers like America.

Foreigners will get the best buzz off German weed

24 Nov 2021

Berlin is preparing to light up its recreational cannabis market. With potential sales taxes and savings of 5 bln euros a year, the move could give the economy added puff. But German players may at first have to play second fiddle to Canadians that dominate the medicinal market.

Capital Calls: Biden’s deficit, Austria lockdown

19 Nov 2021

Concise views on global finance: A nonpartisan analysis finds a $160 billion hole in the U.S. president’s social programs; while new Covid restrictions spark selloff in European airlines and hospitality.

Chancellor: Investors unprepared for carbon crunch

18 Nov 2021

Markets aren’t effectively factoring in a potential hydrocarbons scarcity. It’s not just that the world is trying to get off fossil fuels. They’re increasingly expensive to extract as supplies reach their peak. It’s another downside risk investors need to consider.

Europe’s vaccine bazooka is more like sniper rifle

18 Nov 2021

Germany may join Austria in imposing curbs on the unvaccinated to tackle soaring Covid-19 infections. Restricting freedoms is harsh but worked in France and the United States, which both saw inoculation rates pick up. It also avoids the economic pain of blanket lockdowns.

Ariston IPO is enticing play on green energy wave

17 Nov 2021

The family-owned maker of heat pumps and water heaters is going public in Milan at a valuation of up to 4 bln euros. With demand for energy-efficient heating systems set to boom, it’s in a sweet spot. A discount to rivals A.O. Smith and NIBE Industrier should help inflate demand.

Capital Calls: CalPERS and private equity, Art market

16 Nov 2021

Concise views on global finance: The biggest U.S. public pension fund is taking on more risk; works collected by the Macklowes sold for $676 million on Monday in a reminder that the richest have prospered through the pandemic.

Bad trips reinforce psychedelic industry’s worth

10 Nov 2021

A study showed magic-mushroom drug psilocybin can treat depression. But 5% of patients suffered side-effects like self-harm, hammering shares in $1.5 bln Compass Pathways, which ran the trial. Beating this will take time, money and expertise. Whoever does, has a path to profit.